Wockhardt Limited has informed the Exchange regarding a press release dated October 11, 2024, titled "Wockhardt s yet another novel antibiotic MiqnafTM (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community-Acquired Bacterial Pneumonia (CABP).".